Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Published:2019-03-04 Issue:5 Volume:109 Page:545-552
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Sasaki Koji,Kantarjian Hagop M.,O’Brien Susan,Ravandi Farhad,Konopleva Marina,Borthakur Gautam,Garcia-Manero Guillermo,Wierda William G.,Daver Naval,Ferrajoli Alessandra,Takahashi Koichi,Jain Preetesh,Rios Mary Beth,Pierce Sherry A.,Jabbour Elias J.,Cortes Jorge E.

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-019-02620-2.pdf

Reference20 articles.

1. Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–7.

2. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.

3. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40.

4. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27.

5. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A case report of primary cutaneous diffuse large B-cell lymphoma in chronic myeloid leukemia after treatment with dasatinib;JAAD Case Reports;2024-08

2. Clinical Features of Clonal Cytogenetic Abnormalities in Philadelphia-negative Cells Developed During Tyrosine Kinase Inhibitor Treatment: A Case Series;Internal Medicine;2023

3. Secondary Ovarian Malignancy in an Imatinib treated Chronic Myeloid Leukemia Patient Diagnosed on Fluid Cytology;Clinical Cancer Investigation Journal;2023

4. Follicular Lymphoma Secondary to Chronic Myeloid Leukemia During Treatment With Imatinib;Cureus;2022-11-25

5. Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia;Journal of Oncology Pharmacy Practice;2022-11-07